TP53 and neoplasm: The above findings determined that IRF8 represses p53 to maintain tumor cell sensitivity to ferroptosis, and the loss of IRF8 expression or function decreases tumor cell sensitivity to CTL-induced ferroptosis and promotes tumor growth in vivo.